NEW WEBSITE We would like to invite you to a sneak peak of our new website before it goes live. Visit the new site

Minisymposium: Biomarkers in Drug Discovery – How to Predict for Success in the Clinic



Evaluation: DDD 8 nov 2018

Co-arrangement between SciLifeLab Drug Discovery and Development platform and AstraZeneca

Biomarkers have influence on understanding of disease mechanism, optimize the chance for successful patients’ selection and outcomes of clinical trials and thus may contribute to minimizing cost of a drug development. In drug discovery, the accompanying discovery of potential biomarkers and the subsequent development as tools to identify patients that can benefit from treatment and to demonstrate a pharmacological response to the exploratory drug are therefore of increasing importance. In this minisymposium, we gather international academic and industrial experts to review state-of-the-art and new initiatives. Please, take the chance to discuss your own project with the speakers during the day.

Most welcome!
The organizing committee

Vendela Parrow, Pawel Baranczewski, Rebecka Klintenberg & Kristian Sandberg, SciLifeLab Drug Discovery and Development Platform; Anna Sandström, AstraZeneca



10:00 Introduction

Kristian Sandberg, SciLifeLab/DDD and Anna Sandström, AstraZeneca


10:15 Biomarkers in 21st Century Drug Development

Virginia Byers Kraus, MD, PhD (Durham, North Carolina, US)


11:00 Transforming Drug Research and Development with Genomics’

Jan Fleckner, PhD, AstraZeneca VP, Diagnostic Expert


11:30 Turning a biomarker candidate into a diagnostic for clinical use

Joachim Reischl, AstraZeneca VP, Head of Policy, Portfolio & Externalisation


12:00 Lunch and mingle


13:00 Rigging diagnostics for new predictive biomarkers – the Genomic Medicine Sweden initiative

Johan Botling, MD, PhD, Uppsala University


13:30 Truly Translational – helping the small to think big. Biomarker strategies for SME’s

Karin von Wachenfeldt, PhD, CEO Truly Translational Sweden AB


14:00 SCAN-B: transcriptome profiling of early breast cancer for identification of patients that may benefit from treatment

Åke Borg, PhD, Lund University


14:30 Coffee and mingle


15:00 Biomarkers in the development of KAND567 in acute myocardial infarction

Niclas Brynne, PhD, Chief Development officer at Kancera


15:30 Panel discussion and concluding remarks